
netupitant-palonosetron oral brand names and other generic formulations include:
Akynzeo Oral
ibrutinib oral brand names and other generic formulations include:
Imbruvica Oral
netupitant-palonosetron oral and ibrutinib oral
netupitant-palonosetron oral increases levels of ibrutinib oral by altering drug metabolism.
netupitant-palonosetron oral and ibrutinib oral
netupitant-palonosetron oral increases levels of ibrutinib oral by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib.
Check for more interactions with the Drug Interaction Checker
Drug Interaction Categories
Contraindicated
Never use this combination of drugs because of high risk for dangerous interaction
Serious
Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed
Significant
Potential for significant interaction (monitoring by your doctor is likely required)
Minor
Interaction is unlikely, minor, or nonsignificant